

COPY OF PAPERS  
ORIGINALLY FILED

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

RECEIVED

MAR 29 2002

TECH CENTER 1600/2900

FILE: HACK:009US

TELEPHONE: 512/474-5201  
FAX/SIMILE: 512/536-4598  
WRITER'S INTERNET ADDRESS:  
TBOYCE@FULBRIGHT.COM  
WRITER'S DIRECT DIAL NUMBER:  
512/536-3043

February 27, 2002

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

February 27, 2002  
Date

Thomas M. Boyce

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/065,082 "Hyaluronic Acid as DNA Carrier for Gene Therapy and VEGF Antisense DNA to Treat Abnormal Retinal Vascularization" - P.E. Rakoczy and I.J. Constable

Commissioner:


Enclosed for filing in the above-referenced patent application is:

- (1) A Response to Office Communication dated January 31, 2002;
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10025109/SLH/TMB.

Commissioner for Patents  
February 27, 2002  
Page 2

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Thomas M. Boyce". The signature is written in dark ink and is positioned above the printed name.

Thomas M. Boyce  
Reg. No. 43,508

TMB:lag  
Encl.: As Noted